story of the week
Updated Overall Survival Analysis of Erlotinib vs Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA EGFR+ NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer
J. Clin. Oncol 2022 Aug 26;[EPub Ahead of Print], D Yue, S Xu, Q Wang, X Li, Y Shen, H Zhao, C Chen, W Mao, W Liu, J Liu, L Zhang, H Ma, Q Li, Y Yang, Y Liu, H Chen, Z Zhang, B Zhang, C WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.